secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRI Bio, Inc. (GRI)
CIK:        0001824293
Form:       8-K
Filed at:   2026-05-14T12:36:07+00:00
Accession:  0001824293-26-000046
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GRI Bio Q1 net loss $2.0M; Phase 2a data show zero cough, improved lung function in IPF
--------------------------------------------------------------------------------

- Net loss of $2.0M for Q1 2026 vs. $3.0M in Q1 2025; cash $11.0M, runway into Q2 2027.
- Phase 2a of GRI-0621 in IPF: zero cough in active arm vs 25% placebo; 61% less diarrhea vs placebo despite 67% more nintedanib use.
- Exploratory FVC improvement: +99 mL overall, +139 mL in SOC combination subset vs placebo+SOC.
- Raised ~$6.8M gross via ATM facility in Q1 2026; advancing GRI-0621 toward pivotal studies, GRI-0803 toward IND.
- No SAEs in active arm; single SAE in placebo; patent applications filed based on new data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824293/000182429326000046/0001824293-26-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824293/000182429326000046/val-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001824293-26-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer